Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Association Between Smoking, Brain Activity, Genes, and ADHD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00915798
Recruitment Status : Completed
First Posted : June 8, 2009
Results First Posted : January 13, 2017
Last Update Posted : January 13, 2017
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Jean Gehricke, University of California, Irvine

Brief Summary:
The study investigated the underlying mechanisms of smoking in young adults by examining the associations between smoking, brain activity, dopamine genes, and attention deficit hyperactivity disorder (ADHD).

Condition or disease Intervention/treatment
Smoking Withdrawal Nicotine ADHD Behavioral: Cigarette smoking Behavioral: Abstinence

Detailed Description:
The study investigated the underlying mechanisms of smoking in young adults by examining the associations between smoking, brain activity, dopamine genes, and attention deficit hyperactivity disorder (ADHD). Four groups of young adults were recruited: (1) smokers with ADHD; (2) nonsmokers with ADHD; (3) normative control smokers; and (4) normative control nonsmokers. Smoking was assessed via questionnaires and salivary cotinine levels. Brain activity was examined via functional Magnetic Resonance Imaging (fMRI). Each nonsmoker underwent an fMRI scan during an experimental task consisting of mathematical problems. Smokers underwent two fMRI scans during similar experimental tasks under the following two conditions: (1) after smoking a cigarette and (2) after overnight abstinence. The association between the DRD4-7 repeat allele and smoking was explored.

Layout table for study information
Study Type : Observational
Actual Enrollment : 89 participants
Official Title: Smoking, Neurocircuitry and Genes in Adult ADHD
Study Start Date : July 2009
Actual Primary Completion Date : January 2016
Actual Study Completion Date : June 2016

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Smokers with ADHD
Smokers with ADHD participated in one overnight abstinence condition (withdrawal) and one smoking condition (smoking the first cigarette of the morning).
Behavioral: Cigarette smoking
Participants had an fMRI scan during an experimental task consisting of mathematical problems after smoking a cigarette.

Behavioral: Abstinence
Participants had an fMRI scan during an experimental task consisting of mathematical problems after smoking abstinence.

Nonsmokers with ADHD
Nonsmokers with ADHD participated in one condition.
Behavioral: Abstinence
Participants had an fMRI scan during an experimental task consisting of mathematical problems after smoking abstinence.

Control smokers
Control smokers participated in one overnight abstinence condition (withdrawal) and one smoking condition (smoking the first cigarette of the morning).
Behavioral: Cigarette smoking
Participants had an fMRI scan during an experimental task consisting of mathematical problems after smoking a cigarette.

Behavioral: Abstinence
Participants had an fMRI scan during an experimental task consisting of mathematical problems after smoking abstinence.

Control nonsmokers
Control nonsmokers participated in one condition.
Behavioral: Abstinence
Participants had an fMRI scan during an experimental task consisting of mathematical problems after smoking abstinence.




Primary Outcome Measures :
  1. Brain Activity [ Time Frame: One MRI session for nonsmokers and two MRI sessions for smokers ]
    BOLD z-score of smokers with ADHD after abstinence/smoking a cigarette, control smokers after abstinence/smoking a cigarette, nonsmokers with ADHD, and control nonsmokers. All participants performed a mathematical task in the MRI scanner. Higher BOLD z-scores indicate greater brain activation.


Secondary Outcome Measures :
  1. DRD4 Genotype [ Time Frame: one time blood draw ]
  2. Salivary Cotinine [ Time Frame: Once per week for 4 weeks ]
    Average level of salivary cotinine over all time points (microgram/milliliter)


Biospecimen Retention:   Samples With DNA
Blood samples for genotyping


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Commuity sample
Criteria

Inclusion Criteria:

  1. Smokers with ADHD

    • Cigarette smoking for the last year
    • ADHD diagnosis
  2. Nonsmokers with ADHD

    • No history of regularly smoking cigarettes
    • ADHD diagnosis
  3. Normative control smokers

    • Cigarette smoking for the last year
    • No history and diagnosis of ADHD
  4. Normative control nonsmokers

    • No history of regularly smoking cigarettes
    • No history and diagnosis of ADHD

Exclusion Criteria:

  • Children under the age of 18
  • Adults above the age of 45
  • Pregnancy or planning to become pregnant
  • Any major medical illness
  • Any mental disorders that require medication (except stimulant medication)
  • Any contraindications to fMRI scanning
  • Not speaking English

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00915798


Locations
Layout table for location information
United States, California
2500 Red Hill Avenue
Santa Ana, California, United States, 92705
Sponsors and Collaborators
University of California, Irvine
National Institute on Drug Abuse (NIDA)
Investigators
Layout table for investigator information
Principal Investigator: Jean-G. Gehricke, Ph.D., M.A. University of California, Irvine
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Jean Gehricke, Associate Professor, University of California, Irvine
ClinicalTrials.gov Identifier: NCT00915798    
Other Study ID Numbers: HS 2009-6740
K01DA025131 ( U.S. NIH Grant/Contract )
First Posted: June 8, 2009    Key Record Dates
Results First Posted: January 13, 2017
Last Update Posted: January 13, 2017
Last Verified: November 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No